Table 7.
Rosiglitazone meta-analyses for non-cardiovascular related deaths
| Method (fixed or random effects), and data sources | Single zero event trials | Zero total event trials | Continuity correction | Effect estimate (95% CI) | No of trials |
|---|---|---|---|---|---|
| Peto (fixed) | |||||
| IPD only | Included | Excluded | None | OR 1.42 (0.72 to 2.81) | 16 |
| IPD+RECORD | Included | Excluded | None | OR 0.85 (0.66 to 1.10) | 17 |
| Mantel-Haenszel (fixed) | |||||
| IPD only | Included | Excluded | Constant continuity correction of 0.5 | OR 1.18 (0.64 to 2.17) | 16 |
| RR 1.18 (0.65 to 2.15) | 16 | ||||
| IPD+RECORD | Included | Excluded | OR 0.84 (0.65 to 1.08) | 17 | |
| RR 0.84 (0.66 to 1.08) | 17 | ||||
| IPD only | Included | Included | OR 1.04 (0.62 to 1.73) | 33 | |
| RR 1.04 (0.63 to 1.71) | 33 | ||||
| IPD+RECORD | Included | Included | OR 0.83 (0.65 to 1.06) | 34 | |
| RR 0.84 (0.66 to 1.06) | 34 | ||||
| Dersimonian and Laird (random) | |||||
| IPD only | Included | Excluded | Constant continuity correction of 0.5 | OR 1.18 (0.60 to 2.30) | 16 |
| RR 1.18 (0.61 to 2.28) | 16 | ||||
| IPD+RECORD | Included | Excluded | OR 0.83 (0.64 to 1.07) | 17 | |
| RR 0.83 (0.65 to 1.07) | 17 | ||||
| IPD only | Included | Included | OR 1.01 (0.58 to 1.74) | 33 | |
| RR 1.01 (0.59 to 1.74) | 33 | ||||
| IPD+RECORD | Included | Included | OR 0.82 (0.64 to 1.05) | 34 | |
| RR 0.83 (0.65 to 1.05) | 34 | ||||
| Mantel-Haenszel (fixed) | |||||
| IPD only | Included | Excluded | Treatment arm correction | OR 1.32 (0.71 to 2.45) | 16 |
| RR 1.32 (0.71 to 2.44) | 16 | ||||
| IPD+RECORD | Included | Excluded | OR 0.85 (0.66 to 1.10) | 17 | |
| RR 0.86 (0.67 to 1.10) | 17 | ||||
| IPD only | Included | Included | OR 1.22 (0.73 to 2.06) | 33 | |
| RR 1.22 (0.73 to 2.05) | 33 | ||||
| IPD+RECORD | Included | Included | OR 0.86 (0.67 to 1.10) | 34 | |
| RR 0.87 (0.68 to 1.10) | 34 | ||||
| Dersimonian and Laird (random) | |||||
| IPD only | Included | Excluded | Treatment arm correction | OR 1.25 (0.63 to 2.50) | 16 |
| RR 1.25 (0.63 to 2.48) | 16 | ||||
| IPD+RECORD | Included | Excluded | OR 0.83 (0.64 to 1.08) | 17 | |
| RR 0.84 (0.65 to 1.07) | 17 | ||||
| IPD only | Included | Included | OR 1.16 (0.66 to 2.04) | 33 | |
| RR 1.16 (0.66 to 2.03) | 33 | ||||
| IPD+RECORD | Included | Included | OR 0.84 (0.65 to 1.08) | 34 | |
| RR 0.85 (0.66 to 1.08) | 34 | ||||
IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.
For all analyses, numbers of non-cardiovascular related deaths observed among total population of patients was as follows: IPD only, rosiglitazone population: 22 events among 11 837 patients; IPD only, control population: 13 events among 9319 patients; RECORD, rosiglitazone population: 91 events among 2226 patients; RECORD, control population: 116 events among 2232 patients.